Inibição CDK4/6 na Gestão do Câncer de Mama Metastático HR+/HER2+: Revisão Sistemática e Meta-análise
OncologiaSobre o estudo
- Desenho
- Metanálise
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- Targeted oncology
- Publicado em
- 21 jan 2026
- Citações
- 0
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
CDK4/6 Inhibition in the Management of Metastatic HR+/HER2+ Breast Cancer: Systematic Review and Meta-analysis
Daniel Park, Marian Varda, Sofia Yeremian, Andrew Hwang, Charity Huang
Descritores MeSH
- Cyclin-Dependent Kinase 6
- Protein Kinase Inhibitors
- Cyclin-Dependent Kinase 4
- Breast Neoplasms
- Erb-b2 Receptor Tyrosine Kinases
- Female
- Humans
- Neoplasm Metastasis
Veja também
Estudos relacionados
- CDK4/6 inhibitors combined with fulvestrant for the treatment of HR+/HER2-advanced or metastatic breast cancer: a Bayesian network meta-analysis
- Comparative efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy in HR+/HR2- patients with advanced or metastatic breast cancer: a systematic review and network meta-analysis
- Treatment consequence and adverse events of cyclin-dependent kinase 4/6 inhibitors on patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and meta-analysis
- The Impact of Obesity on Treatment Outcomes in Patients with Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer Receiving CDK 4/6 Inhibitors
- Impact of CDK4/6 inhibitors on health-related quality of life outcomes in patients with metastatic breast cancer: A systematic review and meta-analysis